.RESEARCH HIGHLIGHT.16 October 2024. In the NIAGARA litigation, the addition of perioperative durvalumab to typical procedure for muscle-invasive bladder cancer cells strengthened event-free and overall survival, denoting a new treatment possibility for this problem.